Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9847998 | 0.85 | FOLH1 (0.54) | L3MBTL1MEN1KMT2AFOLH1MME | |
| SCHEMBL9847993 | 0.85 | FOLH1 (0.54) | L3MBTL1MEN1KMT2AFOLH1MME | |
| SCHEMBL3506387 | 0.84 | MME (0.58) | L3MBTL1FOLH1MMEALDH1A1 | |
| SCHEMBL3506385 | 0.84 | MME (0.58) | L3MBTL1FOLH1MMEALDH1A1 | |
| SCHEMBL3705739 | 0.80 | MME (0.43) | L3MBTL1MMEPTPN1CA2ALDH1A1 | |
| SCHEMBL9545901 | 0.80 | MME (0.43) | L3MBTL1MMEPTPN1CA2ALDH1A1 | |
| SCHEMBL3705736 | 0.80 | MME (0.43) | L3MBTL1MMEPTPN1CA2ALDH1A1 | |
| SCHEMBL25356249 | 0.79 | TDP1 (0.57) | L3MBTL1MEN1KMT2ATDP1FOLH1 | |
| SCHEMBL27095768 | 0.79 | TDP1 (0.57) | L3MBTL1MEN1KMT2ATDP1FOLH1 | |
| SCHEMBL458048 | 0.79 | TDP1 (0.57) | L3MBTL1MEN1KMT2ATDP1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210196842-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | US | disclosed |
| WO-2017095806-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-08 | — | — | WO | disclosed |
| EP-2267029-B1 | Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents | BRIGHAM & WOMENS HOSPITAL (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9284541-B2 | Methods and compositions for protein labeling using lipoic acid ligases | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150125904-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-07 | — | — | US | disclosed |
| US-8871456-B2 | Probe incorporation mediated by enzymes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2013148189-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013052851-A1 | METHODS AND COMPOSITIONS FOR POLYPEPTIDE AND PROTEIN LABELING USING LIPOIC ACID LIGASES SPECIFIC TO RESORUFIN | MASSACHUSETTS INISTITUTE OF TECHNOLOGY (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20120214201-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129159-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELING USING LIPOIC ACID LIGASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-24 | — | — | US | disclosed |
| US-20040009176-A1 | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003096877-A2 | PREVENTION AND TREATMENT OF STREPTOCOCCAL AND STAPHYLOCOCCAL INFECTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030105000-A1 | Methods and compositions for inhibiting GRB7 | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2003-06-05 | — | — | US | disclosed |
| US-20030013643-A1 | Prevention and treatment of streptococcal and staphylococcal infection | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2003-01-16 | — | — | US | disclosed |
| WO-2001017557-A9 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1207905-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2002036142-A2 | COMPOSITIONS FOR INHIBITING GRB7 | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020055488-A1 | Prevention and treatment of streptococcal and staphylococcal infection | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2002-05-09 | — | — | US | disclosed |
| WO-2002024223-A2 | PREVENTION AND TREATMENT OF STREPTOCOCCAL AND STAPHYLOCOCCAL INFECTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001017557-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129159-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELING USING LIPOIC ACID LIGASES | LARS1, ACSL5, RARS1 | L3MBTL1 77/4885MEN1 2187/4885KMT2A 2296/4885 |
| US-20210196842-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | DLAT, FABP7, ACSL1 | L3MBTL1 317/4885MEN1 275/4885KMT2A 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.